INTRODUCTION
Estrogen Receptors (ER) and Progesterone Receptors (PR) are both members of the same family of nuclear transcription factors and are coexpressed in many of the same target tissues. There is significant cross-talk between the estrogen and progesterone signaling pathways. Approximately two thirds of ER positive breast tumors that undergo endocrine therapy are also PR positive. How PR influences the outcome of therapies for ER positive tumors is unknown. Complicating this is the fact that PR exist as two naturally-occurring isoforms termed PR-A and PR-B, and these isoforms have been shown to have differential effects on ER-mediated transcription. Interestingly, PR positive primary human breast tumors have greatly varying ratios of PR-A:PR-B. In normal breast tissue and most breast tumors and cell lines, PR are under the regulation of estrogen, which makes it difficult to separate ER and PR effects. One exception are T47Dco human breast cancer cells, which are ER positive but constitutively express both PR-A and PR-B, independent of estrogen regulation. This makes them an excellent model for studying PR action. We have previously isolated a PR negative T47D subline (T47D-Y) and engineered them to express either PR-A (T47D-YA) or PR-B (T47D-YB). As outlined under this grant, we have established a model in which these cell lines can be grown into solid tumors as xenografts in female athymic nude mice. Growth of tumors in vivo occurs in a strictly estradiol-dependent manner. Preliminary data show that the PR status, regardless of ligand, affects estradiol-dependent tumor growth. In particular, cells expressing PR-A grew significantly smaller tumors, on average, than cells expressing no PR or PR-B. These data were presented at two international conferences as found in Appendices / and //. An original article describing these data in detail is in press in Breast Cancer Research and Treatment A copy of this publication is attached to this report as Appendix ///.
B2Jl Role of PR-A vs. PR-B in Estrogen-Dependent Human Breast Thmor Growth
Carol A. Sartorius.Tianjie Shen, and Kathryn B. Horwitz Division of Endocrinology, University of Colorado Health Sciences Center, Denver, CO, USA, 80262.
Approximately two thirds of ER positive human breast tumors that respond to endocrine therapy are also PR positive. However, PR positive tumors contain varying ratios of the two naturally-occurring receptor isoforms, PR-A and PR-B. PR-A and PR-B have different functions in vivo including differential effects on estrogen mediated actions in target tissues. To study how each PR isoform influences tumor growth, we have developed a model system in which human T47D breast cancer cells expressing either PR-A or PR-B are grown into solid tumors in ovariectomized female nude mice. Growth of tumors in vivo occurs in a strictly estradiol-dependent manner. Our data show that PR status, independent of ligand, affects estradioldependent tumor growth. In particular, cells expressing PR-B grow significantly larger tumors, on average, than cells expressing PR-A. This occurs with independently derived PR expressing cell lines and despite the fact that PR-A and PR-B containing cells have approximately equal population doubling times in culture. Addition of both estrogen and progesterone at initial tumor formation did not alter growth patterns. Differences in growth of established tumors were observed, however, between PR-A and PR-B containing tumors treated with either tamoxifen or the antiprogestin RU486. These experiments will help determine which types of tumors may be the best candidates for hormone therapies. This work was supported by DAMD BC996108 and the Cancer League of Colorado.
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Differential Estradiol-Dependent Gene Expression in PR-A vs. PR-B Containing Human Breast Tumor Xenografts Carol A. Sartorius, Tianjie Shen, and Kathryn B. Horwitz Division of Endocrinology, University of Colorado Health Sciences Center, Denver, CO, USA, 80262.
The two isoforms of progesterone receptors (PR), PR-A and PR-B, are expressed at varying ratios in estrogen receptor (ER) positive human breast cancers, and may potentially affect the outcome of endocrine therapies. We have used ER positive T47D human breast cancer cells that express PR-A exclusively or PR-B exclusively to grow solid tumor xenografts m ovariectomized female nude mice. Under chronic estradiol stimulation necessary for tumor growth. PR-A tumors grew consistently smaller than PR-B tumors; this occurred in the absence of PR ligand. We hypothesized that PR-A was specifically repressing ER regulated genes, analogous to that observed in vitro, except in a ligand-independent manner. To identify specific genes whose expression levels were affected by the presence of PR, we performed Affymetrix® gene microchip analyses (Human Genome U95Av2) on RNA isolated fi-om estradiol-treated PR-A and PR-B expressing tumors. Affymetrix and Genespring® software was used to identify a subset of genes which were differentially expressed between the two samples in multiple experiments. Of the 59 genes consistently differentially regulated, 48 were expressed at higher levels m PR-B containing tumore, whereas 11 were expressed at higher levels m PR-A containing tumors. We will present data on specific genes may be important in mediating the differential growth difference between the two types of tumors (PR-A vs. PR-B). We conclude that the PR isoform ratio m prinwry breast tumore is important and should be considered clinically. 
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